FibroGen, Inc. Company Analysis & Research
FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company focuses on anemia, fibrotic disease, and cancer using proprietary expertise in HIF biology and ADC technology.
The company completed a transformative strategic shift, concentrating on its lead asset FG-3246, an Antibody-Drug Conjugate (ADC) for prostate cancer. The sale of the China business for approximately $220 million extended the cash runway into 2028, providing a buffer to reach key clinical milestones.
Company Overview
Founded: 1993. Headquarters: San Francisco, California. Revenue: $29.62 million. Ticker: FGEN (NASDAQ).
Industry
Biopharmaceutical - Oncology and Hematology
Cyborg Score: 6/10 — Solid
Refocused biotech player pivoting to oncology with extended cash runway and first-in-class ADC assets, though facing execution risk in clinical development.
FibroGen faced setbacks with late-stage trials for pamrevlumab in pancreatic cancer failing to meet primary endpoints, leading to program termination and a 75% reduction in U.S. workforce. However, the company has extended financial runway through strategic asset sales and refocused on promising oncology programs with strong patent positions.
Key Strategic Insights for FibroGen, Inc.
- Q3 2025 net income exceeded $200 million following sale of China operations
- Lead product Roxadustat has completed Phase III clinical development for anemia in chronic kidney disease in multiple geographies and Phase III for anemia related with myelodysplastic syndromes
- Strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB
- Pipeline includes FG-3165 and FG-3175, anti-GAL-9 antibodies for treatment of solid tumors
Recent Developments
- (November 2025) Completed sale of China operations for ~$220 million, extending cash runway to 2028
- (2024) Pamrevlumab pancreatic cancer trials failed primary endpoints; program terminated with workforce reduction
- (2024) FDA cleared IND application for FG-3165, monoclonal antibody targeting galectin-9 for solid tumors
Competitors & Competitive Landscape
- Agios Pharmaceuticals / Akebia Therapeutics — Competing HIF pathway modifiers for chronic kidney disease anemia
- Seagen / Pfizer — Large-cap competitors with established ADC platforms in solid tumors
- Other biotech players — Earlier-stage programs targeting connective tissue growth factor pathway
FibroGen competes in the biopharmaceutical space against larger oncology and rare disease specialists. Its focus on first-in-class HIF inhibitors and ADC conjugates differentiates it from competitors like Agios Pharmaceuticals, Akebia Therapeutics, and other mid-cap biotech firms developing anemia and oncology therapeutics.
More Company Research
FORTEC Elektronik AG Severfield plc HMS Bergbau AG LEM Holding F.I.L.A. - Fabbrica Italiana Lapis ed Affini S.p.A. Marcus & Millichap, Inc. The Bank of Nagoya, Ltd. Perdoceo Education Corporation Columbia Sportswear Company Capgemini SE ConvaTec Group PLC Nitori Holdings Co., Ltd. Coles Group Limited Wal-Mart de México, S.A.B. de C.V. CleanCore Solutions, Inc.Full Company Research Reports
Looking for a more in-depth analysis of FibroGen, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, analyst debate audio, and saved-company audio playlists.